Medical Therapy Versus Balloon Sinus Dilation in Adults With Chronic Rhinosinusitis (MERLOT): 12-Month Follow-up. Issue 4 (July 2018)

• Record Type: Journal Article
• Authors: Stolovitzky, J. Pablo; Mehendale, Neelesh; Matheny, Keith E.; Brown, William J.; Rieder, Anthony A.; Liepert, Douglas R.; Tseng, Ewen; Gould, Andrew
• Is Part Of: American journal of rhinology & allergy. Volume 32:Issue 4(2018)
• Page Start: 294
• Page End: 302
• Publication Date: 2018-07
• Subjects: rhinosinusitis -- local anesthesia -- office-based procedures -- quality of life -- balloon dilation -- sinuplasty -- medical management -- Chronic Sinusitis Survey; Nose -- Periodicals; Allergy -- Periodicals; 616.21005
• DOI: 10.1177/1945892418773623
• Languages: English
• ISSNs: 1945-8924

Abstract

Background: Chronic rhinosinusitis (CRS) is a devastating disease affecting nearly 30 million people in the United States. An interim analysis of data from the present study suggested that, in patients who had previously failed medical therapy, balloon sinus dilation (BSD) plus medical management (MM) provides a significant improvement in the quality of life (QOL) at 24 weeks postprocedure compared to MM alone. Objective: The primary objective of this final analysis was to evaluate the durability of treatment effects through the 52-week follow-up. Methods: Adults aged 19 and older with CRS who had failed MM elected either BSD plus MM or continued MM. Patients were evaluated at 2 (BSD arm only), 12, 24, and 52 weeks posttreatment. Balloon dilations were performed either as an office-based procedure under local anesthesia or in the operating room per physicians' and patients' discretion. The primary end point was change in patient-reported QOL as measured by Chronic Sinusitis Survey (CSS) total score from baseline to the 24-week follow-up. Secondary outcomes including changes in CSS, Rhinosinusitis Disability Index (RSDI), and Sino-Nasal Outcome Test (SNOT) total and subscores, sinus medication usage, missed days of work/school, number of medical care visits, and sinus infections from baseline to the 52-week follow-up are reported here within. Results: BSD led to sustained greater improvements in self-reported QOL using the CSS and RSDI total scores with a trend toward improvement in the SNOT-20 total score from baseline to the 52-week follow-up compared to continued MM. There were no changes in medication usage apart from nasal steroid usage for which the MM cohort had an increase in usage. There were no device-related serious adverse events. Conclusion: The current analysis highlights the safety, effectiveness, and durability of BSD in CRS patients aged 19 and older who had previously failed MM.